Millendo Therapeutics Announces Data Presentations for MLE4901 and ATR-101 at ENDO 2017 and Kisspeptin 2017

-- Oral Late-breaking Presentation: Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes --

ANN ARBOR, Mich., Mar. 23, 2017 – Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases caused by hormone dysregulation, today announced that data from its MLE4901 and ATR-101 programs will be presented in multiple poster and oral presentations at The Endocrine Society’s (ENDO) 99th Annual Meeting and Expo, being held April 1-4 at the Orange County Convention and Exhibition Center in Orlando, Florida, and at the Kisspeptin 3rd World Conference, an ENDO satellite meeting, on March 30-31 at the Rosen Centre Hotel in Orlando, Florida.

Details of the MLE4901 program presentations are as follows:

Title: Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial

Meeting: Kisspeptin 2017: Brain & Beyond
Poster: 57
Date/Time: Thursday, March 30, 2017, 9:00 – 11:00 AM EDT
Location: Rosen Centre Hotel

Meeting: ENDO 2017
Oral Session: Late Breaking Developments in Female Reproduction and Menopause Treatment
Date/Time: Monday, April 3, 2017, 12:30 – 12:45 PM EDT
Room: W414A, Orange County Convention and Exhibition Center

Title: Neurokinin B and kisspeptin regulation of gonadotropin secretion and hot flushes in postmenopausal women

Meeting: Kisspeptin 2017: Brain & Beyond
Poster: 71
Date/Time: Thursday, March 30, 2017, 9:00 – 11:00 AM EDT
Location: Rosen Centre Hotel

Title: Trial in Progress: A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase 2b Study of MLE4901, a Novel NK3 Receptor Antagonist, for the Treatment of PCOS

Meeting: ENDO 2017
Poster: SAT 099
Date/Time: Saturday, April 1, 2017, 1:00 – 3:00 PM EDT
Room: Expo Hall, Orange County Convention and Exhibition Center

Title: Disconnect in PCOS: Symptoms Leading to Diagnosis Vs. Most Bothersome Symptoms

Meeting: ENDO 2017
Poster: SAT 101
Date/Time: Saturday, April 1, 2017, 1:00 – 3:00 PM EDT
Room: Expo Hall, Orange County Convention and Exhibition Center
Title: MLE4901, a Neurokinin 3 Receptor Antagonist, Acts Upstream of Pituitary GnRH to Reduce Testosterone Secretion in Male Dogs

Meeting: Kisspeptin 2017: Brain & Beyond
Poster: 64
Date/Time: Friday, March 31, 2017, 9:00 – 11:00 AM EDT
Location: Rosen Centre Hotel

Meeting: ENDO 2017
Poster: SUN 485
Date/Time: Sunday, April 2, 2017, 1:00 – 3:00 PM EDT
Room: Expo Hall, Orange County Convention and Exhibition Center

Details of the ATR-101 program presentations are as follows:

Title: Trial in Progress: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome

Meeting: ENDO 2017
Poster: SAT 410
Date/Time: Saturday, April 1, 2017, 1:00 – 3:00 PM EDT
Room: Expo Hall, Orange County Convention and Exhibition Center

Title: ATR-101 and ER Stress-Inducing Chemotherapeutic Agents Synergize to Induce Cytotoxicity in Adrenocortical Cancer Cells

Meeting: ENDO 2017
Poster: MON 396
Date/Time: Monday, April 3, 2017, 1:00 – 3:00 PM EDT
Room: Expo Hall, Orange County Convention and Exhibition Center

About Millendo Therapeutics, Inc.
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases caused by hormone dysregulation. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are advancing two product candidates in five indications: MLE4901, designed to address Polycystic Ovary Syndrome (PCOS) and Vasomotor Symptoms (VMS), and ATR-101 for the treatment of Classic Congenital Adrenal Hyperplasia (CAH), Endogenous Cushing’s Syndrome (CS), and Adrenocortical Carcinoma (ACC). www.millendo.com

###

Media Contact:
Casey R. Doucette, Ph.D.
MacDougall Biomedical Communications
+1 781 235 3060
cdoucette@macbiocom.com

Investor Contact:
Stephanie Ascher
Stern Investor Relations, Inc.
+1 212 362 1200
stephanie@sternir.com